Mercator Medical S.A. will pay its shareholders a dividend of 15 million zlotys for 2025

The Annual General Meeting of Mercator Medical S.A., held on 30 June 2026, passed a resolution to allocate 15 million PLN towards the payment of a dividend for 2025, amounting to 1.64 PLN gross per share. The dividend amount comprises PLN 6.1 million from the profit generated in 2025 and PLN 8.9 million from retained earnings. The ex-dividend date has been set for 22 July this year, whilst the dividend payment date falls on 5 August this year. The dividend yield, based on a share price of 48.80 zł at the close of trading on the day of the General Meeting, stands at 3.4 per cent. During the Meeting, members of the Supervisory Board were appointed. The shareholders also re-adopted a resolution on the distribution of net profit for 2023. On the same day, the Supervisory Board of Mercator Medical S.A. reappointed the Company’s Management Board in its current composition for a further joint three-year term of office.

– We regard sharing profits with shareholders as an important element of a responsible policy towards the capital market, whilst maintaining the Group’s sound financial structure. Our priority remains maintaining a stable balance sheet position and the ability to finance further growth. This applies in particular to the property segment developed by Mercator Estates, where we plan to continue with property development projects and undertake further capital-intensive investments. We want to finance these in a responsible manner, primarily using our own funds, so as to combine sharing profits with shareholders with the continued building of the Group’s value in the long term – emphasises Monika Żyznowska, Chair of the Management Board of Mercator Medical S.A.

In 2025, the Mercator Medical Group generated over PLN 574.2 million in consolidated sales revenue, representing an increase of just under 6 per cent. The Group achieved an EBITDA of PLN 21.9 million and a net profit of PLN 29.3 million.

During the Annual General Meeting, the Supervisory Board for the new term of office was appointed. Its members once again included Wiesław Żyznowski, Urszula Żyznowska, Piotr Solorz and Wojciech Armuła. Prof. Roman Batko joined the Supervisory Board – an expert with over 30 years’ experience in management, combining academic work with business practice. He is a professor at the Stanisław Staszic University of Science and Technology in Kraków, specialising in quality management, processes and strategy, as well as the digital transformation of enterprises.

On the same day, the Supervisory Board of Mercator Medical S.A. appointed the Company’s Management Board for a further joint three-year term, leaving its composition unchanged. Monika Żyznowska remains in the position of Chair of the Management Board, whilst Dariusz Krezymon and Mariusz Popek will continue to serve as Members of the Management Board. The continuation of the current management team’s work will enable the Company to further implement its adopted strategy and develop key areas of its operations.

At this year’s Annual General Meeting, the shareholders passed a resolution on the voluntary cancellation of 124,000 own shares, which were repurchased by the company in 2025 at a price of 100 zł per share. Last year, the shareholders of Mercator Medical S.A. decided to allocate PLN 12.5 million to the reserve fund to finance a share buy-back programme with a view to their cancellation. The programme, under which the company was authorised to acquire a maximum of 125,000 shares, concluded in August 2025 with the acquisition of 124,000 shares.

***

The Mercator Medical Group, based in Kraków, is a manufacturer of disposable gloves and a distributor of single-use medical supplies. It is one of the leading players in Poland and a significant player on the international stage. The company’s history dates back to 1989. The Mercator Medical Group operates a production centre in Thailand and is involved in distribution activities, including the distribution of products from external suppliers. Its operations are international in scope – sales through its own distribution companies and via external, local distributors take place in several dozen countries around the world; in 2025, the Group sold nearly 5.9 billion disposable gloves. Since November 2013, Mercator Medical S.A. shares have been listed on the regulated market of the Warsaw Stock Exchange. In March 2021, they were included in the main stock market index – the WIG20; they are currently listed on the sWIG80 index.

In 2024, Monika Żyznowska, CEO of Mercator Medical, was appointed to the Issuers’ Council reporting to the Chairman of the Warsaw Stock Exchange.